Carrington Laboratories Inc. (ASE:CRN) of Irving, Texas, said ithas received permission from FDA to begin a pilot safety andefficacy study on acemannan to treat acute flare-up inulcerative colitis patients. Acemannan is a polysaccharide withimmune modulating and anti-viral properties.

(c) 1997 American Health Consultants. All rights reserved.

No Comments